WEEK OF OCTOBER 31, 2022
The Future of Precision and Predictive Health Care
Japan Healthcare Week, featuring Conference Events in Tokyo (Oct. 31) and Awajishima (Nov. 2)
Japan Week Event on October 31st, 2022
Japan Week 2022 | Meet American and Japanese Companies
Tokyo Executive Symposium
Oct 31, 2022
1:00–5:00 PM (JT)
Followed by Networking Reception
Tokyo Executive Symposium:
Nihonbashi Life Science Hub (Link)
Chief Executive Officer,
Fogarty Innovation
Andrew Cleeland is the CEO of Fogarty Innovation. A seasoned executive with more than 30 years of experience in the medical device industry, he has held key leadership positions in organizations ranging from early–stage start–ups to large multinationals.
12:30 P.M. – 1:00 P.M.
REGISTRATION
1:00 P.M. – 1:15 P.M.
OPENING OF SYMPOSIUM
- Steve Pollock | President, Japan Society of Northern California
- Daniel Lew | Commercial Officer, U.S. Embassy, Tokyo
- Akihiko Soyama | President and CEO, Director, LINK-J
1:15 P.M. – 2:05 P.M.
KEYNOTE SPEECH: INNOVATION FOR THE FUTURE OF PREDICTIVE HEALTHCARE
Followed by Q&A session moderated by Dr. Fumiaki Ikeno
Andrew Cleeland is the CEO of Fogarty Innovation. A seasoned executive with more than 30 years of experience in the medical device industry, he has held key leadership positions in organizations ranging from early–stage start–ups to large multinationals.
2:05 P.M. – 2:55 P.M.
SESSION 1: PRECISION, PREDICTIVE, & PROACTIVE HEALTHCARE – BETTER OUTCOMES, LOWER COSTS, AND HIGHER PATIENT SATISFACTION
After graduating from Jichi Medical University, he began practicing general medicine in the rural areas of Japan. Fumiaki joined the Department of Cardiovascular Medicine at Stanford University in 2001, and was closely involved with the R&D, animal studies, and clinical studies of many medical device startups. He is also actively involved in projects with the US and Japanese regulatory agencies working to create an effective cross-border medical device eco-system. Fumiaki has also been an advisory faculty for the Stanford Biodesign Program since 2014. He is deeply involved with the development of the Japan Biodesign Program and is working diligently to establish a Silicon Valley-like medical device eco-system in Japan.
Andrew Cleeland is the CEO of Fogarty Innovation. A seasoned executive with more than 30 years of experience in the medical device industry, he has held key leadership positions in organizations ranging from early–stage start–ups to large multinationals.
Mika is a commercialization executive with extensive leadership experience in conceiving, planning, and launching disruptive medical technologies in 50 markets across North America, EMEA, Asia-Pacific, and Latin America. She has an exceptional track record of leading businesses from inception to across different clinical segments, including cardiovascular, fertility, and oncology.
Ryan has spent 35 years in the Life Sciences and Medical Device industries focusing on innovation and adding value to the companies that drive it. He has worked with numerous companies that have invented novel technologies for a range of markets, including cell and gene therapies, biotherapeutics, biotech instrumentation, in vitro diagnostics, and medical devices. At Triple Ring Technologies, Ryan leads teams of world class scientists and engineers who work at the intersection of patient needs and cutting-edge technology development.
2:55 P.M. – 3:05 P.M.
BREAK
3:05 P.M. – 3:55 P.M.
SESSION 2: PREDICTIVE HEALTHCARE TARGETS
Harry started his career in Japan at Citizen Watch Co. and was soon after transferred to Dubai, New Jersey, and Los Angeles to oversee product development in international markets. Harry left the company as CFO of the US subsidiary, then started a medical device sales company in California as a joint venture with a Japanese medical device company. He struggled with the US medical device business initially but found success after acquiring a small US manufacturer and expanding the business. He exported the products to 25 countries from the United States.
Partha Ray is a mission-driven medtech innovation leader with over 25 years of deal & operating experience at leading global organizations. Partha has launched products and closed deals which benefit over 9M patients and generate over $20B/yr in revenues today.
Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. Elton represents both public and private enterprises as their outside general counsel and serves as a key strategic advisor from their inception throughout their life cycle. He advises on complex venture capital and corporate finance transactions, corporate law and governance, mergers and acquisitions, and public offerings.
Dr. Burnett is a veteran in the medical device industry having founded many successful companies at various stages. During his undergraduate career at the University of Pennsylvania, he focused on bioengineering and spent a year at the Food and Drug Administration both testing devices and writing congressional reports on the current state-of-the-art devices.
Kirk Zeller is a nearly 30 year veteran of the medical device industry with extensive global commercial experience having lived, worked, and studied in US, Europe, and Asia. Kirk is currently the Co-founder of MedMarket Access, LLC and on the boards of Progressive NEURO, Inc, Radux Devices, and MedMarket Access, LLC. Kirk is also the founder of the Silicon Prairie Center, an entrepreneur live and work incubator.
3:55 P.M. – 5:15 P.M.
PRIVATE EARLY STAGE AND PRIVATE COMPANY PRESENTATIONS
Alan Raby is the CEO and Founder of CareMates, a digital care platform for older adults.
Alan has over 30 years of experience in which 20+ years have been spent working in the technology industry globally. He is a serial entrepreneur and intrapreneur. He has ~ 20 years of experience working in Japan and was previously a General Manager with SONY where he was responsible for bringing SONY FeliCa technology, EDY e-money and Osaifu-Keitai from Japan to the US. He is a pioneer in FinTech and launched the first nation wide mobile banking application in the US in 2001.
Founder and CEO of EchoPixel, a startup company pioneering medical imaging VR/AR solutions that are defining a new visualization paradigm Holographic Therapy Guidance (HTG), which allows doctors to perform minimally invasive surgeries using a digital twin of the patient that they experience as a hologram.
Mr. Lichorowic is a highly accomplished serial entrepreneur and chief executive in the field of high tech and medical industries. Starting off in Fortune 500 companies in high tech in Silicon Valley, Mr. Lichorowic crossed into the medical field and now leverages twenty-five years of expertise in big data, machine learning, AR & amp; VR and surgical robotics.
Dean has over 25 years of experience in launching and growing brands in the areas of: medical devices, OTC health/wellness products, digital health apps, medical/pharmaceutical therapeutics, life science start-ups as well as Fortune 25 companies. Dean is currently the Chief Commercial Officer of Intuity Medical Inc., a Silicon Valley MedTech company launching a highly disruptive glucose meter in the diabetes industry.
Jerome has over 30 years of commercial experience in the life science and biotechnology industry in various sales, marketing, and business development roles. His contributions have helped 3 startup companies achieve profitability. He has also held management positions in global organizations such as Becton Dickinson and GE Healthcare. Jerome has a BS in Biochemistry and Cell Biology from the University of California, San Diego and an MBA from San Diego State University.
Shungo ADACHI, Co-founder and Representative Director, has more than 15 years of experience in innovative healthcare management and policy development in Japan and overseas. He has had overall management responsibility for medical cluster projects, working with corporations and providing strategic planning for R&D and operations teams.
David Lapointe
David currently serves as CEO of Optina Diagnostics. Optina’s Retinal Deep Phenotyping platformTM, with the first indication of development being the diagnosis of Alzheimer’s disease, offers non-invasive and more accessible tests. With an early and accurate diagnosis, physicians, patients, and caregivers will have better planning and early treatment options, making the patient journey much easier.
Luiz Augusto (Guto) de Castro e Paula
Guto is the Director of Innovation and Partnerships at Optina Diagnostics, responsible for strategic partnering and working with pharma industry and academic customers. Before taking this role, Guto was the Business Unit Director of Computed Tomography and Molecular Imaging for GE Healthcare for 7 years, where he also held other leadership roles in product and sales for a total of 14 years in that company.
Charles Cielo oversees Intralink’s Life Sciences practice in Japan, helping overseas companies – including Personalis – navigate market entry and find their place in the unique Japanese healthcare ecosystem. A bioengineer by training, scientist by vocation and businessman by trade, he’s proficient in three languages and worked for global big pharma prior to joining Intralink.
5:15 P.M. – 5:30 P.M.
CLOSING REMARKS
5:30 P.M. – 6:30 P.M.
RECEPTION & SOCIAL NETWORKING
